Open Orphan plc (LON:ORPH), a rapidly growing specialist clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has confirmed that an editorial opinion piece regarding
Pharmaceutical services company Open Orphan is expanding its Covid-19 challenge study, inoculating up to 20 further volunteers. The government-funded trial, which is being carried out with subsidiary hVivo, involves deliberately infecting people
Open Orphan’s Cathal Friel discusses progress on a number of fronts in this exclusive interview with DirectorsTalk.
Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO,
Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced a
Clinical research organisation (CRO) Open Orphan has announced that its subsidiary hVIVO has signed a contract with AIM ImmunoTech to test its antiviral candidate, Ampligen, against the human Rhinovirus HRV,
Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO,
The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. It is the US Agency responsible for the regulation of drugs and
Clinical research organisation (CRO) Open Orphan has launched a spin-out organisation targeting the infectious disease market. Biotech Poolbeg Pharma has been created in the wake of the Covid-19 pandemic and
The MedTalk’s Reece Armstrong speaks to Cathal Friel, chairman and co-founder of Open Orphan, about the company’s involvement in setting up the first human challenge study model for Covid-19 and
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
